Brief: Annovis Bio Receives Interim Analysis For Sample Size Re-Estimation For Its Phase 3 Clinical Trial

Annovis Bio

31/03/2023 14:26

March 31 (Reuters) - Annovis Bio Inc  ANVS.N :
    * ANNOVIS BIO - RECEIVED INTERIM ANALYSIS FOR SAMPLE SIZE
RE-ESTIMATION FOR ITS PHASE 3 CLINICAL TRIAL FOR TREATMENT OF
EARLY PARKINSON'S DISEASE
    * ANNOVIS BIO INC - INTENDS TO PROCEED WITH TRIAL AS PLANNED
IN
ACCORDANCE WITH PREVIOUSLY ESTABLISHED PROTOCOL
    * ANNOVIS BIO INC - EXPECTS THAT INTERIM ANALYSIS TO BE
RELEASED
IN THE SECOND QUARTER OF 2023

Further company coverage:  ANVS.N 

 ((Reuters.Briefs@thomsonreuters.com;))